Merck Drug Shown to Work in Treating Male Osteoporosis
According to a study in the New England Journal of Medicine, Merck & Co.'s Fosamax drug, primarily used for the treatment of osteoporosis in women, is also useful in treating the disease in men. The two-year study, led by a team of researchers from the Oregon Health Sciences University, found that the drug was effective in increasing bone density in men, particularly in the spine and hip. Merck announced earlier this year that it is seeking approval from the US Food and Drug Administration to sell the drug to men. For more information, visit www.merck.com.
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
